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1 |  INTRODUCTION
Epithelioid glioblastoma (eGBM) is a rare, recent addition 
to the World Health Organization's (WHO) classification of 
central nervous system (CNS) tumors. We describe a unique 
case of a young woman with a history of ovarian cancer pre-
senting with expressive aphasia and a new left temporal brain 
lesion. Open biopsy provided a diagnosis of eGBM. Here, 
we discuss this unique case and a relevant literature review 
of eGBM.
2 |  CASE REPORT
2.1 | History
A 29‐year‐old woman with past medical history of breast fi-
broadenoma and ovarian juvenile‐type granulosa cell tumor 
at age 14 presented to the emergency room following two 
episodes of disorientation, global aphasia, and left‐sided fa-
cial and lower extremity numbness with paresthesias. The 
patient did not lose consciousness, was somnolent after both 
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Key Clinical Message
Our patient's clinical history and preoperative radiographic evaluation suggested 
central nervous system (CNS) metastatic disease. Ultimately, final pathology re-
vealed epithelioid glioblastoma (eGBM), a newly classified CNS primary tumor. 
This reinforces the importance of direct tissue sampling and including eGBM on the 
differential for young patients with histories of systemic cancer presenting with new 
CNS lesions.
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episodes but recovered, and was able to continue with her 
work that day. Further history revealed the patient had expe-
rienced intermittent headaches during the prior 2 weeks. She 
denied trauma, seizure history, vision changes, gait instabil-
ity, or recent illness.
Patient had a left salpingo‐oophorectomy at age 14. 
Routine follow‐up scans for 5 years after her cancer diag-
nosis suggested remission. Her last menstrual period was 
2 days prior to presentation. Social history revealed the pa-
tient drank socially, never smoked, and she denied drug use. 
Patient's mother had a cerebral vascular abnormality and 
her maternal aunt died of a brain aneurysm. The patient's 
father was diagnosed with rectal cancer at age 37 and died 
of T‐cell lymphoma at age 47. Her paternal grandfather had 
colon and lung cancer at age 47 and died at age 50. Her ma-
ternal grandmother was diagnosed with multiple myeloma at 
age 78.
2.2 | Examination
Vital signs: Temp 99.0ºF, BP 125/77 mm Hg, Pulse 98/min, 
RR 18/min, SpO2 99%, BMI 31.76 kg/m2. She was in no 
acute distress and cooperative throughout the examination. 
The patient was alert and oriented to self, time, and place 
with no focal neurological deficits.
2.3 | Diagnostic imaging, testing, and 
laboratory results
MRI brain with and without contrast demonstrated an intra‐
axial anterior left temporal lobe enhancing mass measuring 
1.5 cm in diameter. The lesion was isointense on T1‐weighted 
images, hyperintense on T2‐weighted images, showed ring 
enhancement on T1 with contrast and had perilesional hyper-
intensity on FLAIR sequence suggestive of vasogenic edema 
(Figure 1). A 21 channel continuous digital EEG performed 
at bedside yielded no epileptiform activity.
Given the patient's history and imaging, a metastatic 
workup was conducted. Relevant laboratory results are high-
lighted in Table 1. CT chest, abdomen, and pelvis were re-
markable for a 1.4 cm × 2.2 cm soft tissue density within the 
left breast consistent with a benign fibroadenoma. A trans-
vaginal ultrasound was performed which demonstrated a 
left salpingo‐oophorectomy and a right ovary that measured 
4 cm × 2.8 cm × 3.7 cm with slightly complex cysts that 
measured 2.1 cm × 1.5 cm × 2.2 cm, consistent with physio-
logic corpus luteal cysts.
2.4 | Hospital course and operation
The patient was admitted to the oncology service with fre-
quent neurological evaluations and started on dexametha-
sone 4 mg every 6 hours and levetiracetam 500 mg twice 
daily. Five days after admission, the patient underwent an 
image‐guided left frontal‐temporal craniotomy. The patient's 
head was secured in a radiolucent skull clamp and an intra‐
operative CT scan obtained in the surgical position was fused 
to a preoperative thin slice postcontrast MRI, and a surgical 
navigation system was registered to the patient with good 
accuracy. She underwent a left temporal craniotomy where 
the subcortical tumor was localized with image guidance and 
was found to be firm and well encapsulated. The lesion was 
removed en bloc and sent for frozen and permanent pathol-
ogy. Frozen section suggested a poorly differentiated malig-
nant metastatic lesion of unknown primary origin.
F I G U R E  1  Preoperative MRI. A, Axial and B, coronal T2 MRI demonstrated a hyperintense left temporal lobe lesion. C, Perilesional 
hyperintensity on FLAIR sequence suggestive of vasogenic edema. D, Postcontrast T1 MRI revealed a solitary enhancing left temporal lobe lesion
T A B L E  1  Relevant laboratory results
Tumor marker Patient value Normal range
CA‐125 17 U/mL <35 U/mL
CEA 1.4 ng/mL 0‐5.0 ng/mL
Inhibin A 4 pg/mL <98.0 pg/mL
Inhibin B 32 pg/mL <153 pg/mL
   | 823FINNERAN Et Al.
A postoperative MRI scan within 24 hours of surgery 
demonstrated gross total resection (Figure 3A). She remained 
neurologically intact and was discharged to home on post‐op 
day number 2 on a steroid taper.
2.5 | Pathologic findings
Histologic sections revealed tumor with large areas of necro-
sis and numerous mitotic figures (Figure 2A). The section 
showed predominantly pleomorphic epithelioid cells show-
ing plump eosinophilic cytoplasm and sharp cell borders 
mimicking a metastatic melanoma or carcinoma (Figure 2B). 
The morphologic features were inconsistent with an ovarian 
juvenile‐type granulosa cell tumor. Immunohistochemistry 
showed that the tumor was positive for GFAP, supporting 
glial differentiation (Figure 2C). Immunostains for mela-
noma including SOX10, HMB45, and S100 were negative. 
An immunostain for p53 also showed diffuse positivity 
and INI‐1 showed no loss of nuclear expression. A reticu-
lin stain revealed absence of an intercellular reticulin mesh-
work. Molecular analyses were also obtained and revealed 
no mutations in the IDH1 and IDH2 genes (wild‐type) and in 
exon V600 of the BRAF gene. Mutations for EGFR variant 
III expression and MGMT promoter methylation were also 
negative. The overall findings were consistent with glioblas-
toma in which the epithelioid type was supported by the cy-
tologic features—namely the sharp cell borders and rounded 
nuclei—that imparted a more epithelioid, rather than glial, 
appearance.
2.6 | Outcome
Four weeks after surgery, the patient underwent fractionated 
partial brain irradiation consisting of 60 Gy over 6 weeks. She 
completed an MRI brain with and without contrast at 3 and 
6 months postoperatively which showed no evidence of tumor 
recurrence (Figure 3). Patient has since refused adjuvant te-
mozolomide therapy and is currently seeking nutritional ther-
apies. She has been seizure‐free on levetiracetam throughout 
her clinical course and remains neurologically intact.
3 |  DISCUSSION
Glioblastoma epithelioid type is a rare tumor. It was 
added to the 4th edition of the World Health Organization 
Classification of Tumors of the Central Nervous System in 
2016.1 According to this classification, glioblastomas are 
largely divided based on isocitrate dehydrogenase‐1 (IDH‐1) 
mutations.2 IDH wild type, or primary glioblastoma, devel-
ops de novo without evidence of a less malignant precursor. 
These tumors compose about 90% of cases and are often seen 
in elderly patients.2 IDH mutant, or secondary glioblastoma, 
progresses from low‐grade astrocytomas and accounts for 
about 10% of cases. Secondary gliomas are more often seen 
in younger patients, frequently in the frontal lobe and carry 
a better prognosis.2 Histologically, the two subgroups are 
mostly indistinguishable with standard stains and the diag-
nosis relies on genetic identification of the IDH‐1 mutation.
F I G U R E  3  Postoperative T1 
postcontrast MRI. A, 24‐hour postoperative 
MRI reveals gross total resection with 
a signal in the posterior resection bed 
consistent with blood products and 
proteinaceous fluid. B, 3‐mo and C, 6‐mo 
postoperative MRIs show T1 hypointensity 
in left temporal lobe without areas of 
residual or new enhancement
F I G U R E  2  Histology. A, Areas of necrosis are appreciated under low magnification H&E staining (arrows; 40×). B, Epithelioid tumor cells 
showing plump eosinophilic cytoplasm and sharp cell borders, mimicking metastatic melanoma or carcinoma (400×). C, Tumor cells expressed 
GFAP by immunohistochemistry, supporting glial origin (400×)
(A) (B) (C)
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The epithelioid type has been added to the classification 
of IDH wild‐type GBM, but it is unique in its predilection for 
younger patients and poorer prognosis.1 The poor prognosis 
may be in part due to an increased propensity for leptomenin-
geal dissemination.3 Diagnosis of eGBM relies on a combina-
tion of radiologic, histologic, and genetic analyses. Radiologic 
features of eGBM include areas of cystic necrosis with nod-
ular enhancement, often accompanied by vasogenic edema 
and associated mass effect.4 Tumor location and morphology 
can assist in differentiating primary brain tumors from sol-
itary intracerebral metastases with contrast‐enhanced MRI. 
Metastases are typically located at gray‐white matter junctions 
and are well‐circumscribed compared to primary tumors. The 
lesion in this case resided within temporal lobe parenchyma 
and was relatively well‐circumscribed, providing a differen-
tial which included both primary brain tumor and metastasis.5 
Though MR spectroscopy and MR perfusion may assist dif-
ferentiating primary brain tumors from solitary brain metas-
tases, these MR sequences were not obtained for this case.6,7
Genetically, eGBM differs from traditional IDH wild‐type 
glioblastomas in that it often lacks identifiers such as EGFR 
amplification.1 Histologically, the differential diagnosis in-
cludes metastatic carcinoma, metastatic melanoma, and pleo-
morphic xanthoastrocytoma (PXA).4,8 Epithelioid GBM 
features large epithelioid cells with abundant eosinophilic cy-
toplasm, vesicular chromatin, multiple mitotic figures, fairly 
extensive necrosis, and prominent nucleoli. The appearance 
of the nucleoli particularly may cause eGBM to be mistaken 
for metastatic melanoma during frozen section analysis. Its 
histology may also closely resemble PXA, a WHO grade II 
lesion, and its anaplastic variant (PXA‐A) as both often exhibit 
pleomorphic and epithelioid cell morphology.8 Distinguishing 
features that are expected in PXA, which were notably absent 
in the presented case, include presence of eosinophilic globules 
(eosinophilic granular bodies) and a rich reticulin meshwork. 
Immunohistochemical stains assist in narrowing the differen-
tial further, as GBM is typically GFAP‐positive, S‐100 pro-
tein‐positive, negative for HBM‐45 and Melan‐A. Metastatic 
melanoma is also S‐100 protein‐, HMB‐45‐, and Melan‐A‐
positive, but metastatic melanomas and carcinomas are GFAP‐
negative.4 Our case was immunostain‐negative for S‐100 and 
SOX10. This is in agreement with reports showing 29% of 
eGBMs are negative for S‐100 and reports showing SOX10 is 
not expressed in all GBM samples.9,10 Molecularly, an increas-
ing number of eGBM cases are showing a BRAF V600E mu-
tation.11 The BRAF mutation could provide clinical relevance, 
as BRAF inhibitor therapy may become a promising option.12
4 |  SUMMARY
Identification and diagnosis of glioblastoma are often 
straightforward; however, eGBM can mimic a metastatic 
tumor radiographically and on frozen section. Therefore, 
establishing a definitive histologic diagnosis may be im-
portant in selected patients suspected of having metastatic 
disease. Given the unique classifications of GBM, it is im-
portant to evaluate brain tumor specimens using histologic 
stains and genetic analysis for detection of eGBM. Due to 
its poor prognosis and predilection for leptomeningeal dis-
semination, early identification and treatment of this lesion 
may improve overall patient outcomes. Here, we discuss a 
29‐year‐old woman with past medical history of ovarian 
cancer presenting with transient receptive aphasia and ra-
diographic evidence of a temporal lesion resembling meta-
static disease. Although the initial impressions on frozen 
section appeared consistent with a metastasis, final histo-
logic and genetic analysis of this lesion revealed eGBM, 
a rare and newly classified subtype of GBM by the WHO 
classification.
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